CA
NZ
UK
AU
IND
US
● Entera Bio closed a BVF Partners-led privatePlacementin July 2026 at $2.04 per share, extending its cash runway into 2030 ahead of a planned Phase 3 start for oral-peptide candidate EB613.
Biotech in 2026 is not one story but many, and this cluster captures the spread. On one end sit companies converting approvals into real, growing revenue; on the other, developers whose science may be promising but whose balance sheets are thin enough to threaten …
● Intelligent Bio Solutions submitted its FDA 510(k) package for the Intelligent Fingerprinting Drug Screening System on September 9, 2026, while carrying going-concern language and about $6.86 million in cash.
Healthcare is the most crowded neighborhood in theNasdaqComposite, and it is also the most fragmented. Within a single sector you can find a device maker scaling revenue at breakneck speed, a small pharma that just turned its first profit, a clinical-stage biotech living from …
Biotech in September 2026 is a market of two moods. Companies with approved products and real revenue are being rewarded for durability, while pre-revenue names live and die on single data points. Liquidia Corporation (NASDAQ:LQDA), RenovoRx (NASDAQ:RNXT), Krystal Biotech (NASDAQ:KRYS), Tenax Therapeutics (NASDAQ:TENX) and …
TheNasdaqComposite has always leaned on its technology giants, but underneath the megacaps sits a crowded field of clinical-stage biotech and health-technology names that trade on catalysts rather thanEarningsmultiples. September 2026 is a useful moment to look closely at five of them, because they span …
Grouping these five tickers together is an exercise in contrast, not comparison. IDEXX Laboratories is a multi-billion-dollar diagnostics compounder with a raised full-year outlook. The other four, Akari Therapeutics, Allarity Therapeutics, Aptevo Therapeutics and Revelation Biosciences, are clinical-stage micro-caps whose value rests on trial …
Biotech and health technology rarely move as one. On any given week theNasdaqComposite houses companies chasing a first product approval alongside others fighting to stay listed. Arrowhead Pharmaceuticals (NASDAQ:ARWR), Whitehawk Therapeutics (NASDAQ:WHWK), Cullinan Therapeutics (NASDAQ:CGEM), DarioHealth (NASDAQ:DRIO) and Maravai LifeSciences (NASDAQ:MRVI) illustrate that spread.
Grouping biotech and health-technology stocks together can flatten some very real differences. In this list, one company is still spending to prove a drug works, another is banking hundreds of millions in quarterly product sales, and a third barely fits the biotech label at …
Healthcare investors spent the first half of 2026 watching biotech shake off a long malaise. As September opens, five Nasdaq-listed names capture the sector's range: Viatris (NASDAQ:VTRS), a global generics and specialty pharma heavyweight; Alkermes (NASDAQ:ALKS), a neuroscience developer with a closely watched orexin …
Please wait processing your request...